HIV is a type of retrovirus that causes serious complications in humans. It generally spreads via the blood, semen, vaginal fluid, pre-ejaculate, or breast milk. The global market for HIV drugs is envisaged to surpass USD 19,000 million by 2019 owing to the recent rise in HIV patient population.
This report aims to provide a comprehensive presentation of the global market for HIV Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HIV Drugs. This report contains market size and forecasts of HIV Drugs in global, including the following market information:
Global HIV Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global HIV Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five HIV Drugs companies in 2022 (%)
The global HIV Drugs market was valued at US$ 24060 million in 2022 and is projected to reach US$ 27490 million by 2029, at a CAGR of 1.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
One of the primary factors catalyzing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.
We surveyed the HIV Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global HIV Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global HIV Drugs Market Segment Percentages, by Type, 2022 (%)
- Multi-Class Combination Products
- Nucleoside Reverse Transcriptase Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Fusion Inhibitors
- Entry Inhibitors - CCR5 Co-Receptor Antagonist
- HIV Integrase Strand Transfer Inhibitors
Global HIV Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global HIV Drugs Market Segment Percentages, by Application, 2022 (%)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Global HIV Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global HIV Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies HIV Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
- Key companies HIV Drugs revenues share in global market, 2022 (%)
- Key companies HIV Drugs sales in global market, 2018-2023 (Estimated), (K Units)
- Key companies HIV Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck
Outline of Major Chapters:
Chapter 1: Introduces the definition of HIV Drugs, market overview.
Chapter 2: Global HIV Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of HIV Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of HIV Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global HIV Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
